Lyra Therapeutics (LYRA) EBIT Margin (2021 - 2025)
Lyra Therapeutics (LYRA) has disclosed EBIT Margin for 5 consecutive years, with 24948.0% as the latest value for Q3 2025.
- On a quarterly basis, EBIT Margin fell 1856749.0% to 24948.0% in Q3 2025 year-over-year; TTM through Sep 2025 was 3780.73%, a 1067515.0% increase, with the full-year FY2023 number at 4308.09%, down 17705.0% from a year prior.
- EBIT Margin was 24948.0% for Q3 2025 at Lyra Therapeutics, down from 4822.95% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 860.98% in Q4 2024 to a low of 137772.73% in Q4 2022.
- A 5-year average of 18018.46% and a median of 4822.95% in 2025 define the central range for EBIT Margin.
- Peak YoY movement for EBIT Margin: tumbled -13274025bps in 2022, then soared 12648711bps in 2023.
- Lyra Therapeutics' EBIT Margin stood at 5032.47% in 2021, then crashed by -2638bps to 137772.73% in 2022, then soared by 92bps to 11285.62% in 2023, then surged by 108bps to 860.98% in 2024, then plummeted by -2998bps to 24948.0% in 2025.
- Per Business Quant, the three most recent readings for LYRA's EBIT Margin are 24948.0% (Q3 2025), 4822.95% (Q2 2025), and 4831.15% (Q1 2025).